Amarin, Eddingpharm agree to develop, commercialize Vascepa in ChinaAmarin Corporation and Eddingpharm announced an exclusive agreement for Eddingpharm to develop and commercialize Vascepa in the territories of the Mainland China, the Hong Kong and Macao Special Administrative Regions and Taiwan for uses that are currently commercialized and under development by Amarin in the United States based on the MARINE, ANCHOR and ongoing REDUCE-IT clinical trials of Vascepa. Under the agreement, Eddingpharm will be responsible for development and commercialization activities in the territory and associated expenses. Amarin will provide development assistance and be responsible for supplying finished, and later bulk, product. Terms of the agreement include up-front and milestone payments to Amarin of up to $169M, including a non-refundable $15M up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154M. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens. Amarin will supply product to Eddingpharm under negotiated supply terms.